ACT Oncology Wins the PACT 2016 Enterprise Award for Emerging Healthcare CompaniesNews , Press Releases
Flemington, N.J., May 19, 2016 – ACT Oncology announced today it has been awarded the Philadelphia Alliance for Capital and Technologies (PACT) 2016 Enterprise Award for Emerging Healthcare companies. The Enterprise Awards, held annually, are the region’s most prestigious business honors for innovative life sciences and technology companies, leaders, and entrepreneurs.
The Enterprise Healthcare Emerging Award recognizes companies that are providing an innovative technology solution that has the potential to make a significant and positive impact on a clinical problem in healthcare. The 20th Annual Enterprise Awards comprised 400 companies vying for awards in 10 categories.
“We’re thrilled to have our work recognized by the Philadelphia Alliance for Capital and Technologies,” said Patricia Devitt, president, ACT Oncology. “By focusing on oncology clinical trial execution for biotech, pharmaceutical, and nonprofit oncology organizations, our solutions help clients succeed in this new era of precision medicine.”
ACT Oncology provides drug development services focused on the design and execution of clinical trials on behalf of innovative life sciences companies and not-for-profit patient organizations. They are an industry leader in oncology clinical trials with unparalleled experience conducting studies across all tumor types and hematology indications.
Recently acquired by Precision for Medicine, Precision and ACT Oncology are continuing to innovate by creating the first comprehensive, fully integrated precision oncology clinical development solution, combining the highest standards in clinical trial management with the most advanced biomarker capabilities and processes.
ACT Oncology surpassed the criteria for eligibility and is particularly known for their dedication to advancements in oncology research, their highly seasoned and well-retained study teams, and their consistent performance in clinical trial execution, resulting in a high rate of repeat business within the small to mid-sized biotech industry.
PACT is a leading resource for fast-growing companies and a driver of entrepreneurship and innovation in the Philadelphia region. The Enterprise Awards are just one facet of PACT, which aims to create a strategic hub for the region’s emerging growth companies in the information technology, clean technology, and healthcare industries, manifesting in a competitive edge for the Greater Philadelphia region.
About ACT Oncology
ACT Oncology is a full-service oncology specialty contract research organization with a clear and consistent focus on providing expert, flexible, and cost-effective support for cutting-edge clinical research. Founded in 2000, ACT Oncology is a leader in the application of metrics-driven project management to optimize multinational oncology drug development. For more information, visit actoncology.com.
About Precision for Medicine
Precision for Medicine supports life sciences companies in the use of biomarkers essential to targeting patients more precisely and effectively. Precision applies novel biomarker approaches to clinical research that take advantage of the latest advancements in science and technology, focusing predominantly around genomics, immune-response assays, global specimen logistics, biomarker analytics, and companion diagnostics solutions. For more information, visit precisionformedicine.com.
# # #
Precision Medicine Group Media Relations
212-686-2650, ext. 3027